摘要
目的探讨胃癌根治术加植入缓释氟尿嘧啶(中人氟安)治疗Ⅲ期胃癌的效果及可行性。方法回顾分析南昌大学第一附属医院2008年12月至2009年11月188例Ⅲ期胃癌临床资料。188例均行胃癌根治术,术中随机分为2组:A:治疗组,术中使用植入缓释氟尿嘧啶,96例;B:对照组,不植入缓释氟尿嘧啶,92例。术后4周均采用静脉化疗,并作随访观察。结果与B组比较,使用植入缓释氟尿嘧啶患者腹腔引流液多,其中78.1%有腹痛、31.2%低热,且腹痛、低热持续的时间均长于对照组(P<0.05),但无其他明显毒副作用。治疗组与对照组相比术后1年内复发率(6.30%∶16.30%)和死亡率(3.02%∶10.87%)均有显著性差异(P<0.05)。结论术中植入缓释氟尿嘧啶安全、可行,可降低Ⅲ期胃癌术后复发率及提高术后生存率,具有一定的临床应用价值。
Objective To explore the feasibility and the efficacy of radical gastrectomy plus implantation of fluorouracil sustained release for stage Ⅲ gastric carcinorma.Methods Clinical materials of 188 cases of stage Ⅲ gastric cancer patieats treated in the First Affiliated Hospital,Nanchang University,from December 2008 to November 2009 were analyzed retrospectively.All cases underwent radical gastrectomy.The patients were randomly divided into two groups：Treatment （A） group,fluorouracil sustained release was implanted intraoperatively（n=96）; control （B） group,fluorouracil sustained release was not used （n=92）.At 4 weeks after surgery,intravenous chemotherapy was given and they were followed up.Results There were no obivious side-effects and complications in group A,except for more abdominal drainage,abdominal pain（78.1%） and low-grade fever（31.3%） than those in group B.The 1 year recurrence rate（6.30%） in group A was much lower than that of group B（16.30%） （P0.05）,and the 1 year death rate（3.02%） of group A was much lower than that of group B（10.08%） （P0.05）,respectively.Conclusions Implanting fluorouracil sustained release at operation is safe and feasible.It can decrease the postoperative recurrence rate and improve the postoperative survival rate of patients with stage Ⅲ gastric cancer.
出处
《中国普通外科杂志》
CAS
CSCD
北大核心
2010年第10期1057-1060,共4页
China Journal of General Surgery
关键词
Ⅲ期胃癌
植入缓释氟尿嘧啶
stage Ⅲ gastric cancer
Fluorouracil Sustained Release
